地塞米松预处理降低改良FOLFOX4联合方案致肝功能异常的临床观察

目的观察改良FOLFOX4联合方案辅助地塞米松预处理引起肝功能异常。方法 2010年11月6日前应用改良FOLFOX4联合方案52例患者为对照组,之后的36例改良FOLFOX4联合方案辅助地塞米松预处理的患者为观察组,予以ALT、AST、TBIL、DBIL、ALB、ChE、PA监测。再考证两组患者之间的相关性。结果对照组ALT、AST升高的发生率较观察组高,但差异无统计学意义(P>0.05)。根据化疗周期发生率统计,对照组发生35例,观察组发生8例,组间差异具有统计学意义(P<0.05)。对照组首次出现肝功能异常的时间较观察组有所提前,但差异无统计学意义(P>0.05)。结论在应用改良FOLFOX4联合方案治疗过程中,肝功能损害的发生率较高,而地塞米松在应用过程中发现能有效改善改良FOLFOX4联合方案对肝功能的影响。

Clinical observation of abnormal liver function caused by modified FOLFOX4 combination regimen with auxiliary dexamethasone pretreatment

Objective To observe abnormal liver function caused by modified FOLFOX4 combination regimen with auxiliary dexamethasone pretreatment.Methods Before November 6,2010,52 patients received modified FOLFOX4 combination regimen as control group,and after November 6,2010,36 patients received modified FOLFOX4 combination regimen with auxiliary dexamethasone as treatment group.The levels of ALT,AST,TBIL,DBIL,ALB,ChE,PA were detected.The relation of the levels between the two groups was compared.Results The rates of increasing ALT and AST in patients of control group were higher than those of teatment group（P0.05）.In the cycle of chemotherapy,there were 8 cases in treatment group and 35 cases in control group with increasing ALT and AST（P0.05）.Compared with treatment group,the initial time of abnormal liver function in control group was shorter,but there was no significant difference（P0.05）.Conclusion In the treatment for the patients with modified FOLFOX4 combination regimen,dexamethasone can improve the liver function effectively.